The High Cost Of Being First

There is a predictable arc to every great pharmaceutical story. First comes disbelief, then euphoria, then inevitability, and finally punishment for having believed too much of your own press.

Novo Nordisk (NVO) reached that final phase in 2025, not because semaglutide stopped working, but because investors forgot how brutally unforgiving this business becomes once expectations drift even slightly ahead of reality

By the middle of last year, Novo was being priced less like a company running one of the most successful chronic-disease franchises in history and more like a cautionary tale about what happens when innovation “slows.”

That diagnosis never made much sense. Semaglutide did not suddenly lose efficacy, physicians did not stop prescribing it, and patients did not wake up one morning cured of obesity or diabetes.

What changed was the market’s tolerance for narrative slippage. When management allowed speculative enthusiasm around next-generation combinations to harden into assumed outcomes, the margin for error collapsed.

When those outcomes proved merely very good rather than miraculous, the stock absorbed the disappointment in one violent move.

This is a familiar mistake for investors who over-index on trial readouts and underweight the mechanics of how drugs actually live in the real world. Peak weight-loss percentages look impressive on slides, but franchises are built in the duller terrain of tolerability, adherence, logistics, and reimbursement.

Semaglutide’s commercial dominance was never about being flashy. It was about being usable, scalable, and durable across millions of patients who stay on therapy long after the novelty wears off.

Those attributes didn’t disappear in 2025. They were simply overshadowed by louder comparisons.

Eli Lilly’s (LLY) success has made this dynamic easier to misread. Lilly has executed exceptionally well, but its triumph has been framed as a referendum on Novo’s decline, which is a category error.

In pharma, being second to market often means designing trials with the benefit of hindsight and pushing differentiation where it photographs best.

That can be very effective in the short term. It can also carry costs that only emerge at scale, when discontinuation rates, tolerability ceilings, and payer scrutiny start to matter more than marginal efficacy gains.

Novo’s more conservative posture has been interpreted as timidity, when in reality it reflects long institutional memory about what sustains a franchise once the applause fades.

The market’s real blind spot last year was access. Coverage statistics looked comforting, but they masked a system that makes persistence difficult even for motivated patients.

Prior authorizations, step edits, and administrative drag quietly erode uptake. Novo misjudged how much friction still existed, and it paid for that miscalculation in credibility.

What’s encouraging about the current reset is not the tone of contrition, but the operational pivot that followed.

Direct partnerships, pharmacy strategies, and a willingness to meet patients outside traditional channels are not marketing flourishes. They are acknowledgments that demand is abundant but fragile.

This is also why oral Wegovy matters more than the usual talking points suggest. Oral delivery is not just a convenience upgrade; it removes a collection of small, cumulative frictions that injectables never fully solved.

Injection aversion, refrigeration anxiety, travel constraints, and the quiet social resistance to long-term self-injection all suppress real-world adoption in ways models struggle to capture.

Pills normalize behavior. Normalized behavior expands markets. That expansion does not require heroic pricing assumptions to be meaningful.

Valuation is where all of this comes back into focus. Novo is currently priced as if its core franchise is nearing exhaustion and its strategic missteps are structural rather than situational.

That’s an aggressive assumption for a company still growing revenues at a pace most large-cap pharma peers would trade handsomely to achieve.

Narrowing focus back to diabetes and obesity is not a retreat; it is a recognition that depth beats breadth when the markets are this large and this underpenetrated.

None of this requires Novo to “beat” Lilly in a theatrical sense. Pharmaceutical rivalries are not prize fights; they are endurance races.

The winners are decided years later, in adherence curves and refill data, not on conference stages. Those who confuse the two tend to arrive late and leave early.

If 2025 was the hangover, 2026 looks less like a miracle cure and more like a glass of water, a quiet morning, and the unpleasant realization that the party never changed the fundamentals – only the mood. I suggest you buy the dip.